Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials
Emmanuel Mitry(Roche (Switzerland)), Philippe Rougier(CHU Dijon Bourgogne), Donato Nitti(University of Padua), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico), G. Portier(CHU Dijon Bourgogne), Harry Bleiberg(Institut Jules Bordet), Laurent Bedenne(CHU Dijon Bourgogne), F Lazorthes(CHU Dijon Bourgogne), Dongsheng Tu(Ontario Institute for Cancer Research), Malcolm J. Moore(University Health Network), Roberto Labianca(Ospedale Papa Giovanni XXIII), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Dominique Elias(Institut Gustave Roussy), Bernard Langer(CHU Dijon Bourgogne), Giancarlo Martignoni(CHU Dijon Bourgogne), Anthony Fields(CHU Dijon Bourgogne), Olivier Bouché(CHU Dijon Bourgogne), Chris J. O’Callaghan(Unknown)
Cited by 582
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k